Bristol-Myers Squibb Co Cedear BMY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ARS 32,180.00
- Day Range
- ARS 31,680.00–31,900.00
- 52-Week Range
- ARS 20,520.00–36,220.00
- Bid/Ask
- ARS 0.00 / ARS 0.00
- Shares Outstanding
- 2.04B
- Market Cap
- —
- Volume/Avg
- 111 / 43
Key Statistics
- Price/Earnings (Normalized)
- 3.51
- Price/Sales
- 0.95
- Dividend Yield (Trailing)
- 3.88%
- Dividend Yield (Forward)
- 3.99%
- Dividend Payment Schedule
- Feb, May, Aug, Nov
- Total Yield
- 3.88%
Company Profile
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 32,500
- Website
- https://www.bms.com
Competitors
Valuation
|
Metric
|
BMY
|
MRK
|
GSK
|
|---|---|---|---|
Price/Earnings (Normalized) | 3.51 | 45.36 | 11.46 |
Price/Book Value | 1.97 | 8.57 | 3.98 |
Price/Sales | 0.95 | 5.43 | 2.13 |
Price/Cash Flow | 3.14 | 16.30 | 9.11 |
Price/Earnings
BMY
MRK
GSK
Financial Strength
|
Metric
|
BMY
|
MRK
|
GSK
|
|---|---|---|---|
Quick Ratio | 1.29 | 0.71 | 0.52 |
Current Ratio | 1.53 | 1.32 | 0.82 |
Interest Coverage | 7.88 | 4.28 | 9.51 |
Quick Ratio
BMY
MRK
GSK
Profitability
|
Metric
|
BMY
|
MRK
|
GSK
|
|---|---|---|---|
Return on Assets (Normalized) | 14.59% | 6.27% | 11.66% |
Return on Equity (Normalized) | 68.67% | 16.68% | 42.98% |
Return on Invested Capital (Normalized) | 21.69% | 9.82% | 22.63% |
Return on Assets
BMY
MRK
GSK
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|>g!&Qg@ | LOCK|F^ | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|?T!HLWT | LOCK|F$f | $630B | |||
| AbbVie Inc
ABBV
| LOCK|NcXH&? | LOCK|jc | $489B | |||
| Merck & Co Inc
MRK
| LOCK|^>?wv@$ | LOCK|k&Y | $359B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|&K<>Ml^g | LOCK|Yp | $344B | |||
| Novartis AG ADR
NVS
| LOCK|$^^!TGXv | LOCK|<Y | $272B | |||
| AstraZeneca PLC
AZN
| LOCK|@LRS?>p | LOCK|r#! | $246B | |||
| Amgen Inc
AMGN
| LOCK|@r$MjM% | LOCK|%pg | $224B | |||
| Gilead Sciences Inc
GILD
| LOCK|gLZ?$k | LOCK|$B | $187B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|b#d^vp | LOCK|zv | $169B |
United States